Health Canada grants two probiotic health claims for Pharmax


- Last updated on GMT

Health Canada grants two probiotic health claims for Pharmax

Related tags Clinical trial

Health Canada is at it again – the Federal Canadian health department has granted more health claims for probiotics, with Pharmax, a Seroyal brand offering a comprehensive line of professional-grade, evidence-based nutraceuticals, receiving two approvals.

Health Canada has approved two claims related to Pharmax’s proprietary human lactic commensal (“HLC”) probiotics, HLC Intensive and HLC Replenish - “Significant reduction in the symptoms of irritable bowel syndrome (“IBS”)” ​and “Effective supplementation of normal intestinal microbiota following antibiotic therapy”.

“Considering that few products in the market target these specific conditions, we are pleased to receive Health Canada’s approval for the two claims related to the treatment of IBS and to post-antibiotic recovery,” ​said Yves Yau, President at Seroyal. 

“This is another example of our ongoing commitment to incorporate safe and effective formulas that reflect the latest evidence-based research. Under the direction of Dr. Nigel Plummer, Pharmax HLC strains were meticulously selected and diligently tested in double-blind, placebo controlled clinical trials.”

The double-blind, placebo controlled Sheffield IBS Trial (Alimentary Pharmacology & Therapeutics​, 2008, Vol. 29, pp. 97-103) tested four strains of high potency HLC probiotics and concluded that Pharmax’s proprietary HLC blend indeed proved effective, decreasing the severity of IBS symptoms and number of days with pain, while improving satisfaction with bowel habits and overall quality of life.  

The Cambridge Probiotic/Antibiotic Clinical Trial (International Immunopharmacology, ​2005, Vol. 5, pp. 1091-1097) revealed that Pharmax’s proprietary HLC blend offers proven post-antibiotic replenishment and care by promoting a healthy microflora.

Related topics Markets

Related news

Follow us


View more